Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America

Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial

Mauricio G Cohen, Cynthia M. Pacchiana, Ramón Corbalán, Jesús E. Isea Perez, Carlos I. Ponte, Elsa Silva Oropeza, Rafael Diaz, Ernesto Paolasso, Daniel Izasa, Marco A. Rodas, Carlos E. Urrutia, Robert A. Harrington, Eric J. Topol, Robert M. Califf

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: Although more than 9500 patients have been enrolled in major clinical trials in Latin America, practice patterns in this region have rarely been examined. We sought to compare characteristics, resource utilization, and outcomes of patients treated for acute coronary syndromes in Latin America with those in North America. Methods: The Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Theraphy Trial (PURSUIT) enrolled 10,948 patients with non-ST-segment elevation acute coronary syndromes, including 585 in Latin America and 4358 in North America. We analyzed regional differences in patient groups, treatment patterns, and outcomes and used logistic regression analysis to identify association of enrollment region and survival. Results: For patients in Latin America, the length of hospital stay was significantly longer (10 [7, 15] days vs 6 [4, 9], P < .001). Angiograms, angioplasty, and bypass surgery were significantly less common in Latin America (46.2%, 17.6%, and 11.3% vs 79.4%, 33.6%, and 19.4%, P < .001). Thirty-day death/myocardial infarction was not significantly higher, although mortality alone was significantly higher (6.8% vs 3.1%, P < .001). After adjustment for baseline characteristics, enrollment in Latin America remained an independent predictor for death at 30 days (odds ratio [OR] [95% confidence interval (CI)] 2.42 [1.60-3.67]) and persisted at 6 months (OR [95% CI] 2.5 [1.8-3.4]). Conclusions: Latin American patients treated for acute coronary syndromes were managed less invasively and were twice as likely as their North American counterparts to die within 6 months. This mortality difference was not explained by imbalances in baseline risk.

Original languageEnglish
Pages (from-to)391-401
Number of pages11
JournalAmerican Heart Journal
Volume141
Issue number3
DOIs
StatePublished - Mar 19 2001
Externally publishedYes

Fingerprint

Latin America
Unstable Angina
Acute Coronary Syndrome
North America
Blood Platelets
Length of Stay
Therapeutics
Odds Ratio
Confidence Intervals
Mortality
Angioplasty
eptifibatide
Angiography
Logistic Models
Myocardial Infarction
Regression Analysis
Clinical Trials
Survival

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America : Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. / Cohen, Mauricio G; Pacchiana, Cynthia M.; Corbalán, Ramón; Isea Perez, Jesús E.; Ponte, Carlos I.; Oropeza, Elsa Silva; Diaz, Rafael; Paolasso, Ernesto; Izasa, Daniel; Rodas, Marco A.; Urrutia, Carlos E.; Harrington, Robert A.; Topol, Eric J.; Califf, Robert M.

In: American Heart Journal, Vol. 141, No. 3, 19.03.2001, p. 391-401.

Research output: Contribution to journalArticle

Cohen, MG, Pacchiana, CM, Corbalán, R, Isea Perez, JE, Ponte, CI, Oropeza, ES, Diaz, R, Paolasso, E, Izasa, D, Rodas, MA, Urrutia, CE, Harrington, RA, Topol, EJ & Califf, RM 2001, 'Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial', American Heart Journal, vol. 141, no. 3, pp. 391-401. https://doi.org/10.1067/mhj.2001.113216
Cohen, Mauricio G ; Pacchiana, Cynthia M. ; Corbalán, Ramón ; Isea Perez, Jesús E. ; Ponte, Carlos I. ; Oropeza, Elsa Silva ; Diaz, Rafael ; Paolasso, Ernesto ; Izasa, Daniel ; Rodas, Marco A. ; Urrutia, Carlos E. ; Harrington, Robert A. ; Topol, Eric J. ; Califf, Robert M. / Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America : Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial. In: American Heart Journal. 2001 ; Vol. 141, No. 3. pp. 391-401.
@article{8822b1fad1e64558b50f155db4c8efcb,
title = "Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America: Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial",
abstract = "Background: Although more than 9500 patients have been enrolled in major clinical trials in Latin America, practice patterns in this region have rarely been examined. We sought to compare characteristics, resource utilization, and outcomes of patients treated for acute coronary syndromes in Latin America with those in North America. Methods: The Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Theraphy Trial (PURSUIT) enrolled 10,948 patients with non-ST-segment elevation acute coronary syndromes, including 585 in Latin America and 4358 in North America. We analyzed regional differences in patient groups, treatment patterns, and outcomes and used logistic regression analysis to identify association of enrollment region and survival. Results: For patients in Latin America, the length of hospital stay was significantly longer (10 [7, 15] days vs 6 [4, 9], P < .001). Angiograms, angioplasty, and bypass surgery were significantly less common in Latin America (46.2{\%}, 17.6{\%}, and 11.3{\%} vs 79.4{\%}, 33.6{\%}, and 19.4{\%}, P < .001). Thirty-day death/myocardial infarction was not significantly higher, although mortality alone was significantly higher (6.8{\%} vs 3.1{\%}, P < .001). After adjustment for baseline characteristics, enrollment in Latin America remained an independent predictor for death at 30 days (odds ratio [OR] [95{\%} confidence interval (CI)] 2.42 [1.60-3.67]) and persisted at 6 months (OR [95{\%} CI] 2.5 [1.8-3.4]). Conclusions: Latin American patients treated for acute coronary syndromes were managed less invasively and were twice as likely as their North American counterparts to die within 6 months. This mortality difference was not explained by imbalances in baseline risk.",
author = "Cohen, {Mauricio G} and Pacchiana, {Cynthia M.} and Ram{\'o}n Corbal{\'a}n and {Isea Perez}, {Jes{\'u}s E.} and Ponte, {Carlos I.} and Oropeza, {Elsa Silva} and Rafael Diaz and Ernesto Paolasso and Daniel Izasa and Rodas, {Marco A.} and Urrutia, {Carlos E.} and Harrington, {Robert A.} and Topol, {Eric J.} and Califf, {Robert M.}",
year = "2001",
month = "3",
day = "19",
doi = "10.1067/mhj.2001.113216",
language = "English",
volume = "141",
pages = "391--401",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Variation in patient management and outcomes for acute coronary syndromes in Latin America and North America

T2 - Results from the Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial

AU - Cohen, Mauricio G

AU - Pacchiana, Cynthia M.

AU - Corbalán, Ramón

AU - Isea Perez, Jesús E.

AU - Ponte, Carlos I.

AU - Oropeza, Elsa Silva

AU - Diaz, Rafael

AU - Paolasso, Ernesto

AU - Izasa, Daniel

AU - Rodas, Marco A.

AU - Urrutia, Carlos E.

AU - Harrington, Robert A.

AU - Topol, Eric J.

AU - Califf, Robert M.

PY - 2001/3/19

Y1 - 2001/3/19

N2 - Background: Although more than 9500 patients have been enrolled in major clinical trials in Latin America, practice patterns in this region have rarely been examined. We sought to compare characteristics, resource utilization, and outcomes of patients treated for acute coronary syndromes in Latin America with those in North America. Methods: The Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Theraphy Trial (PURSUIT) enrolled 10,948 patients with non-ST-segment elevation acute coronary syndromes, including 585 in Latin America and 4358 in North America. We analyzed regional differences in patient groups, treatment patterns, and outcomes and used logistic regression analysis to identify association of enrollment region and survival. Results: For patients in Latin America, the length of hospital stay was significantly longer (10 [7, 15] days vs 6 [4, 9], P < .001). Angiograms, angioplasty, and bypass surgery were significantly less common in Latin America (46.2%, 17.6%, and 11.3% vs 79.4%, 33.6%, and 19.4%, P < .001). Thirty-day death/myocardial infarction was not significantly higher, although mortality alone was significantly higher (6.8% vs 3.1%, P < .001). After adjustment for baseline characteristics, enrollment in Latin America remained an independent predictor for death at 30 days (odds ratio [OR] [95% confidence interval (CI)] 2.42 [1.60-3.67]) and persisted at 6 months (OR [95% CI] 2.5 [1.8-3.4]). Conclusions: Latin American patients treated for acute coronary syndromes were managed less invasively and were twice as likely as their North American counterparts to die within 6 months. This mortality difference was not explained by imbalances in baseline risk.

AB - Background: Although more than 9500 patients have been enrolled in major clinical trials in Latin America, practice patterns in this region have rarely been examined. We sought to compare characteristics, resource utilization, and outcomes of patients treated for acute coronary syndromes in Latin America with those in North America. Methods: The Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Theraphy Trial (PURSUIT) enrolled 10,948 patients with non-ST-segment elevation acute coronary syndromes, including 585 in Latin America and 4358 in North America. We analyzed regional differences in patient groups, treatment patterns, and outcomes and used logistic regression analysis to identify association of enrollment region and survival. Results: For patients in Latin America, the length of hospital stay was significantly longer (10 [7, 15] days vs 6 [4, 9], P < .001). Angiograms, angioplasty, and bypass surgery were significantly less common in Latin America (46.2%, 17.6%, and 11.3% vs 79.4%, 33.6%, and 19.4%, P < .001). Thirty-day death/myocardial infarction was not significantly higher, although mortality alone was significantly higher (6.8% vs 3.1%, P < .001). After adjustment for baseline characteristics, enrollment in Latin America remained an independent predictor for death at 30 days (odds ratio [OR] [95% confidence interval (CI)] 2.42 [1.60-3.67]) and persisted at 6 months (OR [95% CI] 2.5 [1.8-3.4]). Conclusions: Latin American patients treated for acute coronary syndromes were managed less invasively and were twice as likely as their North American counterparts to die within 6 months. This mortality difference was not explained by imbalances in baseline risk.

UR - http://www.scopus.com/inward/record.url?scp=0035089316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035089316&partnerID=8YFLogxK

U2 - 10.1067/mhj.2001.113216

DO - 10.1067/mhj.2001.113216

M3 - Article

VL - 141

SP - 391

EP - 401

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 3

ER -